Activation of δ-opioid receptors inhibits L-type Ca(2+) current and transient outward K(+) current in rat ventricular myocytes. 2008

Yuan-Yuan Lin, and Dong-Mei Wu, and Lei Liu, and Qing-Hua Liu, and Zhe-Yi Yan, and Bo-Wei Wu
Department of Physiology, Shanxi Medical University, Taiyuan 030001, China.

In the present study, whole-cell patch-clamp technique was used to observe the effects of SNC162, a selective agonist of δ-opioid receptors, on L-type Ca(2+) current (I(Ca-L)) and transient outward K(+) current (I(to)) in rat ventricular myocytes. The results showed that SNC162 significantly inhibited I(Ca-L) and I(to) in rat ventricular myocytes. The maximal inhibition rate of I(Ca-L) and I(to) reached (46.13±4.12)% and (36.53±10.57)%, respectively. SNC162 at 1×10(-4) mol/L inhibited the current density of I(Ca-L) from (8.98±0.40) pA/pF to (4.84±0.44) pA/pF (P<0.01, n=5) and inhibited that of I(to) from (18.69±2.42) pA/pF to (11.73±1.67) pA/pF (P<0.01, n=5). Furthermore, the effects of naltrindole, a highly selective antagonist of δ-opioid receptors, on I(Ca-L) and I(to) were also observed. The results showed that naltrindole alone had no effects on I(Ca-L) and I(to), while it abolished the inhibitory effects of SNC162 on I(Ca-L) and I(to). In conclusion, SNC162 concentration-dependently inhibited I(Ca-L) and I(to) in rat ventricular myocytes via activation of the δ-opioid receptors, which may be a fundamental mechanism underlying the antiarrhythmic effect of activating δ-opioid receptors.

UI MeSH Term Description Entries
D009271 Naltrexone Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. Antaxone,Celupan,EN-1639A,Nalorex,Naltrexone Hydrochloride,Nemexin,ReVia,Trexan,EN 1639A,EN1639A
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006352 Heart Ventricles The lower right and left chambers of the heart. The right ventricle pumps venous BLOOD into the LUNGS and the left ventricle pumps oxygenated blood into the systemic arterial circulation. Cardiac Ventricle,Cardiac Ventricles,Heart Ventricle,Left Ventricle,Right Ventricle,Left Ventricles,Right Ventricles,Ventricle, Cardiac,Ventricle, Heart,Ventricle, Left,Ventricle, Right,Ventricles, Cardiac,Ventricles, Heart,Ventricles, Left,Ventricles, Right
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D001549 Benzamides BENZOIC ACID amides.
D015221 Potassium Channels Cell membrane glycoproteins that are selectively permeable to potassium ions. At least eight major groups of K channels exist and they are made up of dozens of different subunits. Ion Channels, Potassium,Ion Channel, Potassium,Potassium Channel,Potassium Ion Channels,Channel, Potassium,Channel, Potassium Ion,Channels, Potassium,Channels, Potassium Ion,Potassium Ion Channel
D017465 Receptors, Opioid, delta A class of opioid receptors recognized by its pharmacological profile. Delta opioid receptors bind endorphins and enkephalins with approximately equal affinity and have less affinity for dynorphins. Opioid Receptors, delta,Receptors, delta,Receptors, delta Opioid,delta Receptors,delta Opioid Receptor,delta Receptor,Opioid Receptor, delta,Receptor, delta,Receptor, delta Opioid,delta Opioid Receptors
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

Yuan-Yuan Lin, and Dong-Mei Wu, and Lei Liu, and Qing-Hua Liu, and Zhe-Yi Yan, and Bo-Wei Wu
April 1999, Yonsei medical journal,
Yuan-Yuan Lin, and Dong-Mei Wu, and Lei Liu, and Qing-Hua Liu, and Zhe-Yi Yan, and Bo-Wei Wu
August 1995, The Journal of physiology,
Yuan-Yuan Lin, and Dong-Mei Wu, and Lei Liu, and Qing-Hua Liu, and Zhe-Yi Yan, and Bo-Wei Wu
November 1989, The American journal of physiology,
Yuan-Yuan Lin, and Dong-Mei Wu, and Lei Liu, and Qing-Hua Liu, and Zhe-Yi Yan, and Bo-Wei Wu
April 1994, The American journal of physiology,
Yuan-Yuan Lin, and Dong-Mei Wu, and Lei Liu, and Qing-Hua Liu, and Zhe-Yi Yan, and Bo-Wei Wu
December 1990, The Journal of pharmacology and experimental therapeutics,
Yuan-Yuan Lin, and Dong-Mei Wu, and Lei Liu, and Qing-Hua Liu, and Zhe-Yi Yan, and Bo-Wei Wu
September 1993, Cardiovascular research,
Yuan-Yuan Lin, and Dong-Mei Wu, and Lei Liu, and Qing-Hua Liu, and Zhe-Yi Yan, and Bo-Wei Wu
November 2001, The Journal of physiology,
Yuan-Yuan Lin, and Dong-Mei Wu, and Lei Liu, and Qing-Hua Liu, and Zhe-Yi Yan, and Bo-Wei Wu
September 2000, British journal of pharmacology,
Yuan-Yuan Lin, and Dong-Mei Wu, and Lei Liu, and Qing-Hua Liu, and Zhe-Yi Yan, and Bo-Wei Wu
February 1995, Journal of cardiovascular pharmacology,
Yuan-Yuan Lin, and Dong-Mei Wu, and Lei Liu, and Qing-Hua Liu, and Zhe-Yi Yan, and Bo-Wei Wu
February 2000, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!